Value to Whom? Incorporating Patient Perspectives into Value Assessment for Novel Cell and Gene Therapies August 01, 2020 Share this page Developed by Health Advances in collaboration with the Partnership to Improve Patient Care and the EveryLife Foundation for Rare Diseases Value Assessment Patient-Focused Drug Development (PFDD) Related Articles EveryLife Foundation for Rare Diseases is now the RARE Foundation September 08, 2026 More than 500 Advocates Participated in RARE Across America 2026 August 31, 2026 Breaking News: The FDA has released the draft goals letter for PDUFA VIII August 13, 2026 See All News